Human MSLN Stable Cell Line - CHO-K1

The human MSLN gene, located on chromosome 16p13.3, encodes a preproprotein that undergoes proteolytic cleavage to generate two distinct products: megakaryocyte potentiating factor (MPF), a cytokine that stimulates bone marrow megakaryocyte colony formation, and mesothelin, a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein involved in cell adhesion. Mesothelin is normally expressed at low levels on mesothelial cells lining the pleura, pericardium, and peritoneum, but is significantly overexpressed in several malignancies including malignant pleural mesothelioma, ovarian cancer, pancreatic adenocarcinoma, and certain squamous cell carcinomas. The Human MSLN Stable Cell Line - CHO-K1 is a genetically engineered Chinese hamster ovary cell line that constitutively expresses full-length human mesothelin on the cell surface. This stable line was generated through transfection of the human MSLN coding sequence into CHO-K1 cells followed by antibiotic selection and clonal isolation, ensuring consistent and uniform mesothelin expression across passages.

This stable cell line serves as a valuable tool in oncology and immunotherapy research, particularly for the development and evaluation of mesothelin-targeted therapeutics. It is widely used in functional assays to screen and characterize anti-mesothelin antibodies, bispecific T cell engagers, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR)-T cell therapies. Researchers use these cells as target cells in co-culture cytotoxicity assays to assess the potency and specificity of mesothelin-directed immune effector cells. The line also supports binding and internalization studies, flow cytometry panel development, and immunohistochemistry protocol optimization. Because CHO-K1 cells lack endogenous mesothelin expression, the system provides a clean background for evaluating target-specific responses without interference from native protein. Additionally, the stable line can be adapted for high-throughput screening campaigns in drug discovery pipelines aimed at identifying novel compounds or biologics that modulate mesothelin activity or block its interaction with binding partners such as MUC16/CA125.